News

Hosted on MSN10mon
Pfizer's drug for advanced lung cancer shows promising long-term trial results
Lorbrena is already approved in the U.S. for treating adults with advanced non-small cell lung cancer who have a mutation in a gene called ALK. Pfizer will present the results on Friday at the ...
Hosted on MSN10mon
Pfizer Highlights 'Unprecedented' 5 Year Data From Cancer Drug In Rare Form Of Advanced Lung Cancer
On Friday, Pfizer Inc (NYSE:PFE) released longer-term follow-up results from the Phase 3 CROWN trial evaluating Lorbrena (lorlatinib) available in Europe as Lorviqua versus Xalkori (crizotinib ...
pharmaphorum4y
Will new data make Pfizer's Lorbrena a ‘no-brainer’ in early lung cancer?
Pfizer has taken a big step towards positioning Lorbrena as a worthy heir to its big-selling Xalkori drug in lung cancer, after beating its parent in a phase 3 trial. The CROWN trial pitted ...